Fundamental analysis: Biocept, Inc. (BIOC)

Awarener score: 3.0

Conclusion

The higher the Awarener score, the more bang you get for the buck. It measures how much genuine funds the company generates for the stock price paid (Bottom), the business stability (Bottom) and growth (Superb), and the company's inclination to return cash to the stockholders (Very poor).

Note: All scores range from 1 (worst) to 10 (best). Conclusions are updated daily with closing stock prices and new reported quarterly financial statements.

Revenue score: 5.5

Business has been growing at an extremely fast pace. It's been top tier when measured against peer companies.
Biocept, Inc. business varies wildly, ups and downs could be very frequent. It's very risky. It looks bottom tier against rivals.

Margins score: 1.8

BIOC profit margins -on goods and services sold- are usually destitute. They stand bottom tier against rival companies.
Business profit on sales tends to be extremely poor. It's weak when measured against competitors.
Profits on sales made -available to repay debt and purchase properties- are usually extremely poor. They remain in a very weak position compared to peers.
Earnings -before income taxes and interests on loans taken- tend to be extremely poor in relation to total revenues. They're still worse than most similar companies.
Profits -before income taxes- are usually extremely poor considering total sales, and remain substantially worse when measured against rivals.
Total net profit tends to be extremely poor when confronted to sales. Company stands substantially worse when measured against comparable firms.

Growth score: 1.0

Biocept, Inc. couldn't always profit -on goods and services sold- in the past years. It's been a disappointment compared to competitors.
In recent years, the firm hasn't always been able to profit from operations, which has been bottom tier against comparable firms.
In past years, the company couldn't always turn a profit -available to repay debt and purchase properties-, which compares last-in-rank when measured against peer enterprises.
In the previous years, the firm couldn't always make a profit -before income taxes and interests on loans taken-. It turns to be a disappointment compared to similar stocks.
In past years, at least once the company lost money -before income taxes-. It was bottom tier against rivals.
In the previous years, the firm had at least a total net loss, and last-in-rank when measured against peer companies.
The company lost money at least once in the past years. It's been a disappointment compared to industry peers.

Miscellaneous score: 5.0

BIOC had still to pay income taxes, even though in recent past years mostly lost money. It's been bottom tier against peers.
Research and development expenses consume some portion of revenues. It's similar to competitors.
The company shows very good business growth in relation to research and development efforts. It stands impressive in relation to rival companies.

Profitability score: 1.0

Biocept, Inc. usually gets pauper returns on the resources it controls. It proves last-in-rank when measured against peer firms.
The company normally gets extremely poor proceeds -on the resources directly invested in the business-. They remain a disappointment compared to similar companies.
There's usually bottom profitability -in relation to owned resources-. It ranks last-in-rank when measured against competitors.
In the past, got pauper returns -on the tangible resources it controls-. This metric is usually related to the industry in which operates and combines profitability versus reinvestment needs. It's last-in-rank when measured against comparable enterprises.

Usage of Funds score: 2.0

BIOC on average doesn't generate genuine funds, so to buy or replace property, plants and equipment must either burn existing cash or increase debt. It stands last-in-rank when measured against rival firms.
The company is usually replacing most of the property, plant, and equipment that gets old, and saving a little funds for something else, which is almost average when measured against industry peers.
In the past twelve months the stock paid no dividends. It came bottom tier against competitors.
The company pays no dividend, so measuring its growth is meaningless. The company has behaved in an conservative way compared to similar firms.
As no dividends are paid, it is useless trying to estimate their sustainability in time. Sustainability looks not applicable in regard to comparable companies.
The company has greatly enlarged the pool of investors in previous years, resulting in more mouths feeding on the pie of profits. It remains a disappointment compared to peer enterprises.
Repurchase effectiveness metric is very complex. Run again in analytical mode if you're interested in a technical explanation. It stands in a very weak position compared to rivals.
We do not have sufficient data to comment on buybacks and their sustainability. It still looks dubious against competitors.

Balance Sheet score: 5.6

Biocept, Inc. has no intangible assets (like brands and goodwill) according to accounting books, which is safest. It happens to be top tier when measured against peer companies.
The company has a lot more short-term resources than short-term obligations. Liquidity concerns are most likely irrelevant. It turns to be in good shape compared to similar firms.
A significant part of resources controlled were provided for with financial debt. Creditors have almost as many claims on the company as shareholders. It remains somewhat worse than rival firms.
A substantial portion of resources controlled are already cash or short-term investments, which is better for liquidity. It looks more than average in relation to rivals.
For every dollar of short-term obligations, the company has abundant dollars in cash and short-term receivables. It's in good shape compared to peer firms.
For every dollar of short-term obligations, the company has enough dollars in cash and equivalents, which is somewhat better than similar enterprises.
Usually, sales are on somewhat more than three months credit. It still ranks substantially worse when measured against peers.
Normally has approximately somewhat less than one month of sales worth in inventory. It comes up as excellent in relation to competitors.
On average, it takes higher than four months from the purchase to charging customers. It happens to be slightly worse than peers.
On average pays suppliers two months after the purchase. It ranks almost average when measured against industry peers.
The company pays its suppliers roughly three months before charging its customers, so there's sufficient money invested in working capital. It's rather normal in relation to similar companies.
Has usually been losing money on the business, so net interest expenses must be paid by increasing borrowings, which is unsustainable in the long run. The situation is very risky for both creditors and shareholders, profitability must increase. It stands bottom tier against rival firms.
Business has usually been operated at a loss. Unless prospects improve, the company is no position to decrease loans taken levels but by additional shareholders' funding. Profitability must improve. It ranks last-in-rank when measured against comparable enterprises.
Revenues are reasonable in relation to property, plant, and equipment required to operate. This metric is likely dependent on the industry the company operates in. The more property, plant, and equipment used, the more the company must reinvest to fight obsolescence, which usually means less available funds for the shareholders in the long run. It looks rather normal in relation to similar firms.
Resource exploitation is very good when yearly sales are considered. This metric is normally tied to the industry where the firm belongs. It's still better than most peer companies.

Valuation score: 3.9

Biocept, Inc. reported losses, so valuating it in relation to earnings is meaningless. It happens to be last-in-rank when measured against competitors.
Price-to-Tangible-Book-Value is a fairly complex metric. Run again in analytical mode if you're interested in a technical explanation. It remains impressive in relation to peers.
In the past twelve months, the company consumed funds. Either it reinvested significantly in the business or genuine fund generation might be struggling, which stands somewhat worse than similar companies.
The company usually consumes plenty more funds than can genuinely generate. Business needs are meet by borrowing money or consuming preexistent cash, which can only keep up until a certain limit. Unless the company is driving outstanding business growth, genuine profitability may be brought into question. It's still last-in-rank when measured against industry firms.
In the past twelve months, the company has largely enlarged the pool of investors by issuing new shares. Future profits need to be high enough to justify the measure, as the pie of earnings will now be split among a lot more stockholders. It came up in a weak position compared to peer ventures.
The company is somewhat indebted, loan repayment needs to be taken into account. It looks somewhat worse than similar enterprises.
Considering the past twelve months, traditional Price-to-Earnings relation has been negative, as the company lost money. It ranks last-in-rank when measured against peer companies.
Comparing the current stock price with the past twelve-months revenues gives a very low relationship. One common cause includes profitability being very poor. It looks impressive in relation to rival firms.
The stock price is significantly below the accounting book value. Unless profitability is extremely low, the stock may be selling at a large discount. Pay attention to the other key indicators for hints. The company remains top-notch against peer firms.
In the past twelve months, the operating business lost plenty of money. It happens to be substantially worse when measured against industry peers.
In an alternate metric of bang for the buck, the company has usually shown an extremely low earnings power ability when measured against the current stock price and financial position. Profitability is significantly in dispute. It's still a disappointment compared to peer companies.

Total score: 3.2

Company at a glance: Biocept, Inc. (BIOC)

Sector, industry: Healthcare, Diagnostics & Research

Market Cap: 0.01 billions

Revenues TTM: 0.06 billions

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.